Skip to main content
Premium Trial:

Request an Annual Quote

GenomiQa, Max Kelsen to Codevelop AI Treatment Prediction Tools

NEW YORK (GenomeWeb) – Software firm Max Kelsen and analytics startup GenomiQa said today that they have partnered in a new project to combine artificial intelligence and genomics for the advancement of precision medicine.

The two Australian companies plan to collaborate to develop predictive analysis tools that can improve patient care, including improved models to predict how individuals may respond to various cancer treatments.

"With the rate of increase in healthcare costs, we won't be able to afford 21st century healthcare if we don't use 21st century methods to select treatments," GenomiQa Cofounder John Pearson said in a statement.

A spin-out company of QIMR Berghofer Medical Research Institute, GenomiQa currently offers informatic analysis of genomic data to inform healthcare decisions for hospitals, clinicians, and other customers.